Anagrelide

Current understanding

Platelet-lowering agent for ET; reduces megakaryocyte maturation. Efficacy on thrombocytosis with cardiovascular side effects.

2026-07-22 — Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance: Phase 3 RCT (trial-late): anagrelide serving as active comparator arm vs ropeginterferon alfa-2b (P1101) at 12 months in HU-resistant/intolerant ET — first prospective head-to-head against a long-acting pegylated interferon in this second-line population. (novelty: 3)
2026-05-23 — PharmaEssentia to Present New Clinical Data Supporting Ropeginterferon Alfa-2b in Essential Thrombocythemia at ASCO and EHA 2026: cross-connection with ropeginterferon-besremi: SURPASS-ET two-year post-hoc analysis specifically examines outcomes in ET patients transitioning from anagrelide to ropeginterferon, directly linking the two cytoreductive options in a sequencing context. (novelty: 3)
2026-04-14 — Ropeginterferon Alfa-2b Yields Durable Responses in Essential Thrombocythemia: SURPASS-ET (Phase 3 RCT, trial-late): anagrelide underperformed as the comparator arm with only 6% response vs 43% for ropeginterferon alfa-2b at months 9–12 in HU-intolerant/refractory ET. (novelty: 4)